DEVELOPMENT AND CHARACTERIZATION OF INDOMETHACIN-LOADED MUCOADHESIVE NANOSTRUCTURED LIPID CARRIERS FOR TOPICAL OCULAR DELIVERY
Keywords:Indomethacin, Topical ocular delivery, Nanostructured lipid carriers, Polyethylene glycol, Mucoadhesion
Objective: To develop and characterize indomethacin loaded-nanostructured lipid carriers (IND-NLCs) for topical ophthalmic delivery with different particle sizes and polymer coating to improve the mucoadhesive property on the ocular surface.
Methods: Nanostructured lipid carriers (NLCs) with different solid lipids and surfactants were prepared by the high-pressure homogenization technique. The optimized IND-NLCs was coated with polyethylene glycol 400 (PEG). The physicochemical properties and entrapment efficacy (EE) were examined. In vitro release studies were investigated using the shake-flask method. Ex vivo mucoadhesive studies were assessed by the wash-off test. In addition, the cytotoxicity was assessed by the short time exposure test.
Results: IND-NLCs of ~300 and ~40 nm in diameter were successfully produced with a zeta potential of -30 mV and EE of 60â€“70 %. IND-NLCs prepared with Tween 80 as surfactant could be sterilized by autoclaving. The PEG coating of IND-NLCs did not affect either the particle size or EE. In vitro release showed a prolonged release for 360 min with a burst release of 50-60% occurring within 5 min. The smaller-sized IND-NLCs showed slightly faster release rates and better mucoadhesion to cornea compared to the larger IND-NLCs. PEG-coated IND-NLCs showed the highest mucoadhesion. In addition, IND-NLCs showed less cytotoxicity compared to IND alone.
Conclusion: The small and PEG-coated NLCs represents a potentially useful carrier for safe delivery of indomethacin to the ocular surface with increased residence time.
Weber M, Kodjikian L, Kruse FE, Zagorski Z, Allaire CM. Efficacy and safety of indomethacin 0.1% eye drops compared with ketorolac 0.5% eye drops in the management of ocular inflammation after cataract surgery. Acta Ophthalmol 2013;91:e15-21.
Vulovic N, Primprac M, Stupar M, Ford JL. Some studies into the properties of indomethacin suspensions intended for ophthalmic use. Int J Pharm 1989;55:123-8.
Ahuja M, Dhake AS, Sharma SK, Majumdar DK. Topical ocular delivery of NSAIDs. AAPS J 2008;10:229-41.
Hippalgaonkar K, Adelli GR, Hippalgaonkar K, Repka MA, Majumdar S. Indomethacin-loaded solid lipid nanoparticles for ocular delivery: development, characterization, and in vitro evaluation. J Ocul Pharmacol Ther 2013;29:216-28.
Nagai N, Ito Y, Okamoto N, Shimomura Y. A nanoparticle formulation reduces the corneal toxicity of indomethacin eye drops and enhances its corneal permeability. Toxicology 2014;319:53-62.
Ammar HO, Salama HA, Ghorab M, Mahmoud AA. Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride. AAPS PharmSciTech 2009;10:808-19.
Balguri SP, Adelli GR, Majumdar S. Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues. Eur J Pharm Biopharm 2016;109:224-35.
Andonova V, Zagorchev P, Katsarov P, Kassarova M. Eye drops with nanoparticles as drug delivery system. Int J Pharm Pharm Sci 2015;7:431-5.
Battaglia L, Serpe L, Foglietta F, Muntoni E, Gallarate M, Del Pozo Rodriquez A, et al. Application of lipid nanoparticles to ocular drug delivery. Expert Opin Drug Delivery 2016;13:1743-57.
SÃ¡nchez-LÃ³pez E, Espina M, Doktorovova S, Souto EB, Garcia ML. Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eyeâ€“part II-ocular drug-loaded lipid nanoparticles. Eur J Pharm Biopharm 2017;110:58-69.
Li H, Chen M, Su Z, Sun M, Ping Q. Size-exclusive effect of nanostructured lipid carriers on oral drug delivery. Int J Pharm 2016;511:524-37.
Alvarez-Trabado J, Diebold Y, Sanchez A. Designing lipid nanoparticles for topical ocular drug delivery. Int J Pharm 2017;532:204-17.
Beloqui A, Solinis MA, Rodriguez-Gascon A, Almeida AJ, Preat V. Nanostructured lipid carriers: promising drug delivery systems for future clinics. Nanomedicine 2016;12:143-61.
Novakova L, Matysova L, Havlikova L, Solich P. Development and validation of HPLC method for determination of indomethacin and its two degradation products in the topical gel. J Pharm Biomed Anal 2005;37:899-905.
Niamprem P, Rujivipat S, Tiyaboonchai W. Development and characterization of lutein-loaded SNEDDS for enhanced absorption in caco-2 cells. Pharm Dev Technol 2014;19:735-42.
El-Badry M, Fetih G, Fathy M. Improvement of solubility and dissolution rate of indomethacin by solid dispersions in Gelucire 50/13 and PEG4000. Saudi Pharm J 2009;17:217-25.
Chaiyasan W, Srinivas SP, Tiyaboonchai W. Mucoadhesive chitosan-dextran sulfate nanoparticles for sustained drug delivery to the ocular surface. J Ocul Pharmacol Ther 2013;29:200-7.
Takahashi H, Tajima K, Hattori T, Yamakawa N, Ito N, Goto H. Novel primary epithelial cell toxicity assay using porcine corneal explants. Cornea 2015;34:567-75.
Chaiyasan W, Praputbut S, Kompella UB, Srinivas SP, Tiyaboonchai W. Penetration of mucoadhesive chitosan-dextran sulfate nanoparticles into the porcine cornea. Colloids Surf B 2017;149:288-96.
Wroblewska K, Kucinska M, Murias M, Lulek J. Characterization of new eye drops with choline salicylate and assessment of their irritancy by in vitro short time exposure tests. Saudi Pharm J 2015;23:407-12.
Sakaguchi H, Ota N, Omori T, Kuwahara H, Sozu T, Takaqi Y, et al. Validation study of the short time exposure (STE) test to assess the eye irritation potential of chemicals. Toxicol In Vitro 2011;25:796-809.
Takahashi Y, Hayashi T, Watanabe S, Hayashi K, Koike M, Aisawa N, et al. Inter-laboratory study of short time exposure (STE) test for predicting eye irritation potential of chemicals and correspondence to globally harmonized system (GHS) classification. J Toxicol Sci 2009;34:611-26.
AraÃºjo J, Gonzalez E, Egea MA, Garcia ML, Souto EB. Nanomedicines for ocular NSAIDs: safety on drug delivery. Nanomedicine 2009;5:394-401.
Stroobants A, Fabre K, Maudgal PC. Effect of non-steroidal anti-inflammatory drugs (NSAID) on the rabbit corneal epithelium studied by scanning electron microscopy. Bull Soc Belge Ophtalmol 2000;276:73-81.
Doktorovova S, Souto EB, Silva AM. Nanotoxicology applied to solid lipid nanoparticles and nanostructured lipid carriersâ€“a systematic review of in vitro data. Eur J Pharm Biopharm 2014;87:1-18.
MÃ¼ller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Delivery Rev 2002;54 Suppl:S131-S55.
Huang ZR, Hua SC, Yang YL, Fang JY. Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion. Acta Pharmacol Sin 2008;29:1094-102.
Seyfoddin A, Shaw J, Al-Kassas R. Solid lipid nanoparticles for ocular drug delivery. Drug Delivery 2010;17:467-89.
Seyfoddin A, Al-Kassas R. Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir. Drug Dev Ind Pharm 2013;39:508-19.
Thang LQ, Hanh ND, Duong DQ. Study on cause-effect relations and optimization of exemestane-loaded nanostructured lipid carriers. Int J Pharm Pharm Sci 2017;9:68-74.
Jenning V, ThÃ¼nemann AF, Gohla SH. Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm 2000;199:167-77.
Muchtar S, Abdulrazik M, Frucht-Pery J, Benitaa S. Ex-vivo permeation study of indomethacin from a submicron emulsion through albino rabbit cornea. J Controlled Release 1997;44:55-64.
Paliwal R, Rai S, Vaidya B, Khatri K, Goyal AK, Mishra N, et al. Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomedicine 2009;5:184-91.
Duarah S, Pujari K, Durai RD, Narayanan VHB. Nanotechnology-based cosmeceuticals: a review. Int J Appl Pharm 2016;8:8-12.
Baudouin C, Labbe A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res 2010;29:312-34.
MH, Gowda DV, Vindru J, Moin A. Nanotechnology for ophthalmic preparations. Int J Curr Pharm Res 2016;8:5-11.
Pardeike J, Weber S, Matsko N, Zimmer A. Formation of a physical stable delivery system by simply autoclaving nanostructured lipid carriers (NLC). Int J Pharm 2012;439:22-7.
Ibrahim SS, Awad GAS, Geneidi A, Mortada ND. Comparative effects of different cosurfactants on sterile prednisolone acetate ocular submicron emulsions stability and release. Colloids Surf B 2009;69:225-31.
Gupta H, Aqil M, Khar RK, Ali A, Bhatnagar A, Mittal G. Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery. Nanomedicine 2010;6:324-33.
Kashanian S, Rostami E. PEG-stearate coated solid lipid nanoparticles as levothyroxine carriers for oral administration. J Nanopart Res 2014;16:1-10.
De Campos AM, Sanchez A, Gref R, Calvo P, Alonso MJ. The effect of a PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa. Eur J Pharm Sci 2003;20:73-81.
Deore S, Shahi SR, Dabir P. Nanoparticle: as targeted drug delivery system for depression. Int J Curr Pharm Res 2016;8:7-11.
Jiao J. Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery. Adv Drug Delivery Rev 2008;60:1663-73.